| Title |
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
|
|---|---|
| Published in |
Vascular Health and Risk Management, June 2016
|
| DOI | 10.2147/vhrm.s83088 |
| Pubmed ID | |
| Authors |
Holly E Gurgle, Karen White, Carrie McAdam-Marx |
| Abstract |
Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| Unknown | 132 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 26 | 20% |
| Researcher | 14 | 11% |
| Student > Bachelor | 13 | 10% |
| Student > Postgraduate | 12 | 9% |
| Other | 11 | 8% |
| Other | 24 | 18% |
| Unknown | 33 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Biochemistry, Genetics and Molecular Biology | 7 | 5% |
| Nursing and Health Professions | 7 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Other | 13 | 10% |
| Unknown | 42 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2016.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Vascular Health and Risk Management
#541
of 804 outputs
Outputs of similar age
#225,308
of 353,659 outputs
Outputs of similar age from Vascular Health and Risk Management
#10
of 12 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,659 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.